Straits Times Index
3,367.90 +29.33 (+0.88%) S&P 500
5,471.28 -3.81 (-0.07%) Dow
39,144.29 -25.23 (-0.06%) Nasdaq
17,880.28 +0.98 (+0.01%) Bitcoin USD
62,538.37 +5.38 (+0.01%) CMC Crypto 200
1,346.22 +1.71 (+0.13%)
BEAM Aug 2024 17.500 call
| Previous close | 7.13 |
| Open | 7.39 |
| Bid | 5.40 |
| Ask | 8.60 |
| Strike | 17.50 |
| Expiry date | 2024-08-16 |
| Day's range | 7.13 - 7.39 |
| Contract range | N/A |
| Volume | |
| Open interest | 7 |
ZacksBeam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study
Beam Therapeutics (BEAM) doses the first patient in a phase I/II study, evaluating in vivo base editor BEAM-302 for treating alpha-1 antitrypsin deficiency.
GlobeNewswireBeam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the first patient was treated with BEAM-302, an investigational in vivo base editing medicine designed to precisely correct the underlying cause of severe alpha-1 antitrypsin deficiency (AATD), that is currently being evaluated in a Phase 1/2 clinical trial. “Treating the first patient with BEAM-302 is an i
- GlobeNewswire
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
MADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported data highlighting its optimized, closed and automated manufacturing process for its base-edited CD34+ hematopoietic stem and progenitor cell (HSPC) genetic medicines in a poster presentation at the European Hematology Association (EHA) Hybrid Congress. The optimized process is deployed for the manufacturing of BEAM-10
